Bicara Therapeutics (BCAX) Other financing activities (2024 - 2026)

Bicara Therapeutics' Other financing activities history runs 3 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Other financing activities rose 243.91% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $3.9 million (up 101.61% YoY), while the FY2025 annual figure was $2.8 million, up 72.26% from the prior year.
• Other financing activities for Q1 2026 stood at $1.6 million, down from $1.7 million in the prior quarter.
• The five-year high for Other financing activities was $1.7 million in Q4 2025, with the low at $60000.0 in Q3 2024.
• The 3-year median for Other financing activities is $436000.0 (2025), against an average of $661000.0.
• Peak annual rise in Other financing activities reached 2149.35% in 2025, while the deepest fall reached 89.85% in 2025.
• Bicara Therapeutics' Other financing activities stood at $77000.0 in 2024, then surged by 2149.35% to $1.7 million in 2025, then fell by 8.66% to $1.6 million in 2026.
• Business Quant data shows BCAX's Other financing activities at $1.6 million in Q1 2026, $1.7 million in Q4 2025, and $436000.0 in Q3 2025.